Brokerage Firm Rating Update on Eli Lilly and Company (LLY)

Eli Lilly and Company (LLY) : Zacks Investment Research ranks Eli Lilly and Company (LLY) as 3, which is a Hold recommendation. 9 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. 1 more believe that the stock has more downside risks, hence they propose a Strong Sell. A total of 3 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 13 research analysts is 1.77, which indicates as a Buy.

Eli Lilly and Company (LLY) : 11 Wall Street analysts covering Eli Lilly and Company (LLY) believe that the average level the stock could reach for the short term is $95.73. The maximum price target given is $116 and the minimum target for short term is around $55, hence the standard deviation is calculated at $17.14.


For the current week, the company shares have a recommendation consensus of Buy. Also, Argus Research maintains its view on Eli Lilly and Company (NYSE:LLY) according to the research report released by the firm to its investors. The shares have now been rated Buy by the stock experts at the ratings house. Argus Research raises the price target from $90 per share to $95 per share on Eli Lilly and Company. The rating by the firm was issued on August 2, 2016.

Eli Lilly and Company (NYSE:LLY): The stock opened at $78.49 and touched an intraday high of $78.885 on Wednesday. During the day, the stock corrected to an intraday low of $78.26, however, the bulls stepped in and pushed the price higher to close in the green at $78.59 with a gain of 0.10% for the day. The total traded volume for the day was 2,972,177. The stock had closed at $78.51 in the previous trading session.

Eli Lilly and Company (Lilly) is engaged in drug manufacturing business. The Company discovers, develops, manufactures and market products in two segments: human pharmaceutical products and animal health products. The Companys products are sold in approximately 120 countries. The Companys human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. Its animal health business segment operates through the Companys Elanco division, which develops, manufactures and markets products for both food animals and companion animals. The Company manufactures and distributes its products through facilities in the United States, Puerto Rico and 11 other countries. Its products include endocrinology products, neuroscience products, oncology products, cardiovascular products, products for food animals, products for companion animals and Novartis AH products.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.